Skip to main content

Table 2 Methylation frequencies in the analyzed sample cohorts assessed by quantitative methylation-specific polymerase chain reaction

From: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

Samples/Biomarkers CNRIP1 FBN1 INA SNCA MAL SPG20 § Biomarker panel
Colon Cancer Cell Lines* 20/20 (100%) 18/20 (90%) 19/20 (95%) 18/20 (90%) 19/20 (95%) 20/20 (100%) 20/20 (100%)
Adenomas Test Set 54/60 (90%) 41/60 (68%) 25/60 (42%) 33/60 (55%) 51/60 (85%) 45/60 (75%) 54/60 (90%)
Adenomas Validation Set 47/51 (92%) 36/51 (71%) 14/51 (27%) 26/51 (51%) 42/51 (82%) 42/51 (82%) 49/51 (96%)
Adenomas Combined (Test and Validation Sets) 101/111 (91%) 77/111 (69%) 39/111 (35%) 59/111 (53%) 93/111 (84%) 87/111 (78%) 103/111 (93%)
CRC Test Set 73/74 (99%) 60/74 (81%) 49/74 (66%) 54/74 (73%) 68/74 (92%) 67/74 (91%) 73/74 (99%)
CRC Validation Set 96/105 (91%) 82/105 (78%) 68/105 (65%) 65/105 (62%) 94/105 (90%) 92/105 (88%) 95/105 (90%)
Normal Mucosa Matching CRC Validation Set 42/105 (40%) 2/105 (2%) 0/105 (0%) 0/105 (0%) 3/105 (3%) 0/105 (0%) 4/105 (4%)
CRCs Combined (Test and Validation Sets) 169/179 (94%) 142/179 (79%) 117/179 (65%) 119/179 (66%) 162/179 (91%) 159/179 (89%) 168/179 (94%)
Normal Mucosa Test Set 1/51 (2%) 1/51 (2%) 0/51 (0%) 0/51 (0%) 1/51 (2%) 1/51 (2%) 1/51 (2%)
Normal Mucosa Validation Set 5/59 (8%) 0/59 (0%) 0/59 (0%) 0/59 (0%) 1/59 (2%) 0/59 (0%) 1/59 (2%)
Normals Combined (Test and Validation Sets) 6/110 (5%) 1/110 (1%) 0/110 (0%) 0/110 (0%) 2/110 (2%) 1/110 (1%) 2/110 (2%)
  1. Abbreviation: CRC, colorectal cancer.
  2. * Colon Cancer Cell lines have been analyzed using qualitative methylation-specific PCR.
  3. § Previously published results [9].
  4. † Simultaneous methylation of two or more of the six markers provides a positive biomarker panel.